| Literature DB >> 32946782 |
Kuglae Kim1, Tao Che1, Ouliana Panova2, Jeffrey F DiBerto1, Jiankun Lyu3, Brian E Krumm1, Daniel Wacker1, Michael J Robertson2, Alpay B Seven2, David E Nichols4, Brian K Shoichet3, Georgios Skiniotis5, Bryan L Roth6.
Abstract
Hallucinogens like lysergic acid diethylamide (LSD), psilocybin, and substituted N-benzyl phenylalkylamines are widely used recreationally with psilocybin being considered as a therapeutic for many neuropsychiatric disorders including depression, anxiety, and substance abuse. How psychedelics mediate their actions-both therapeutic and hallucinogenic-are not understood, although activation of the 5-HT2A serotonin receptor (HTR2A) is key. To gain molecular insights into psychedelic actions, we determined the active-state structure of HTR2A bound to 25-CN-NBOH-a prototypical hallucinogen-in complex with an engineered Gαq heterotrimer by cryoelectron microscopy (cryo-EM). We also obtained the X-ray crystal structures of HTR2A complexed with the arrestin-biased ligand LSD or the inverse agonist methiothepin. Comparisons of these structures reveal determinants responsible for HTR2A-Gαq protein interactions as well as the conformational rearrangements involved in active-state transitions. Given the potential therapeutic actions of hallucinogens, these findings could accelerate the discovery of more selective drugs for the treatment of a variety of neuropsychiatric disorders.Entities:
Keywords: GPCR; LSD; psychedelic; sertotonin receptor; signal transduction; structural biology
Mesh:
Substances:
Year: 2020 PMID: 32946782 PMCID: PMC7593816 DOI: 10.1016/j.cell.2020.08.024
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582